(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040138 A1

(51) International Patent Classification[7]: C07D 261/02, 307/14, 307/38, 319/12, 213/38, 233/54, 249/02, 277/10, 327/04, 333/20, 307/81, 235/14, A61K 31/341, 31/422, 31/426

(21) International Application Number: PCT/EP2004/011104

(22) International Filing Date: 5 October 2004 (05.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03023342.3 15 October 2003 (15.10.2003) EP

(71) Applicant *(for all designated States except US)*: **NEWRON PHARMACEUTICALS S.P.A.** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SALVATI, Patricia** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT). **CACCIA, Carla** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT). **MELLONI, Piero** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT). **RESTIVO, Alessandra** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT). **SABIDO DAVID, Cibele** [IT/IT]; Via L. Ariosto, 21, I-20091 Bresso (IT). **VALLESE, Stefania** [IT/IT]; c/o Nikem, Via Zambeletti, 25, I-20021 Baranzate di Bollate (IT).

(74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Plinio, 63, I-20129 Milano (IT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES



(I)

(57) Abstract: This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR^7 group; R^1 is C_3-C_8 alkyl, or C_1-C_8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy; R^2, R^3 are independently hydrogen, C_1-C_6 alkyl, halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy; R^4 is hydrogen, C_1-C_8 alkyl; R^5, R^6 are independently hydrogen, C_1-C_3 alkyl, optionally substituted by hydroxy or phenyl; R^7 is hydrogen or straight or branched C_1-C_3 alkyl; Het is a five to seven membered, saturated or unsaturated heteromonocyclic or an eight to ten membered, saturated or unsaturated heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said mono- or bicyclic groups being optionally substituted by C_1-C_6alkyl, halogen, hydroxyl or C_1-C_6 alkoxy; and the pharmaceutically acceptable salts or prodrug thereof, that are active as sodium and/or calcium channel modulators and/or as selective MAO-B inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

WO 2005/040138 A1